Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the addition of bevacizumab to Abraxane as
second-line therapy in Her-2 negative, hormone receptor negative metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania